Cerebral Necrosis, Nashopharyngeal Cancer, Nerve Growth Factor
Conditions
Brief summary
Cerebral radiation necrosis (CRN) is a well-documented late complication of radiation therapy for cancers, and may have a devastating effect on the patient's quality of life (QOL). However,CRN was once regarded as a progressive and irreversible disease, no standard therapy has been suggested for CRN. In our clinical practice, we have used nerve growth factor(NGF) to treat CRN, and found that GM1 can successfully reverse CRN. A case report has been published in Journal of Clinical Oncology (JCO) in 2011. So we carried out this prospective study to test the efficacy of NGF for CRN.
Interventions
DRUGNGF group
This group will be treated with NGF 18u per day im for 60 days
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* The necrotic mass shown on MRI must be measured in two dimensions. No local or regional recurrence, no distant metastasis. Karnofsky performance status of at least 70 and were supposed to live more than 6 months.
Exclusion criteria
* CRN combined with local or regional relapse, or with distant metastasis. * CRN combined with other cerebrovascular disease. * CRN combined with the second primary malignancy. * CRN without neurologic symptoms or signs. * CRN combined with diabetes. * CRN patients that were supposed to live less than 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy of using NGF for treating CRN | 6-8 months |
Countries
China
Outcome results
None listed